Literature DB >> 24205767

Midterm results with Birmingham Hip Resurfacing/Synergy stem modular metal-on-metal total hip arthroplasty.

Hazem A H Hosny1, Sreebala C M Srinivasan, Jonathan Keenan, Helmy Fekry.   

Abstract

Large head modular metal-on-metal total hip replacement (MoMTHR) has been shown to have increased revision rates in the National joint registry and in literature. We reviewed 41 consecutive patients with 44 hips who had large head MoM THR using a Birmingham Hip Resurfacing (BHR) cup/Synergy stem combination between June 2005 and Nov 2009 with a mean followup of 59.5 months. In this series we had a revision rate of 6.8% (3/44) for adverse reaction to metal debris (ARMD), persistent groin pain and instability. Kaplan-Meier analysis showed a mean cumulative survival rate of 79.2% (95% CI: 75.5%-82.9%) In addition there is a subset of 5/44 patients (113%) with mild grade groin pain who may need revision in the future. Based on these findings, we do not recommend performance of large head MoMTHR in the future.

Entities:  

Mesh:

Year:  2013        PMID: 24205767

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  3 in total

1.  Large-diameter metal-on-metal total hip arthroplasty: dislocation infrequent but survivorship poor.

Authors:  Adolph V Lombardi; Keith R Berend; Michael J Morris; Joanne B Adams; Michael A Sneller
Journal:  Clin Orthop Relat Res       Date:  2014-11-04       Impact factor: 4.176

2.  Midterm results of 36 mm metal-on-metal total hip arthroplasty.

Authors:  Hawar Akrawi; Fahad S Hossain; Stefan Niculescu; Zaid Hashim; Arron Biing Ng; Ajit Shetty
Journal:  Indian J Orthop       Date:  2016 May-Jun       Impact factor: 1.251

Review 3.  Prevalence of Failure due to Adverse Reaction to Metal Debris in Modern, Medium and Large Diameter Metal-on-Metal Hip Replacements--The Effect of Novel Screening Methods: Systematic Review and Metaregression Analysis.

Authors:  Aleksi Reito; Olli Lainiala; Petra Elo; Antti Eskelinen
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.